To the Editor The Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV) trial1 was designed to determine the effects of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition with evolocumab (in statin-treated patients) on progression of coronary atherosclerosis, calculated as the change in PAV.
Alkhalil M, Choudhury RP. Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis. JAMA. 2017;317(16):1690–1691. doi:10.1001/jama.2017.3443
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: